Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial
dc.contributor.author | Nichols, Anthony C | |
dc.contributor.author | Lang, Pencilla | |
dc.contributor.author | Prisman, Eitan | |
dc.contributor.author | Berthelet, Eric | |
dc.contributor.author | Tran, Eric | |
dc.contributor.author | Hamilton, Sarah | |
dc.contributor.author | Wu, Jonn | |
dc.contributor.author | Fung, Kevin | |
dc.contributor.author | de Almeida, John R | |
dc.contributor.author | Bayley, Andrew | |
dc.contributor.author | Goldstein, David P | |
dc.contributor.author | Eskander, Antoine | |
dc.contributor.author | Husain, Zain | |
dc.contributor.author | Bahig, Houda | |
dc.contributor.author | Christopoulous, Apostolos | |
dc.contributor.author | Hier, Michael | |
dc.contributor.author | Sultanem, Khalil | |
dc.contributor.author | Richardson, Keith | |
dc.contributor.author | Mlynarek, Alex | |
dc.contributor.author | Krishnan, Suren | |
dc.contributor.author | Le, Hien | |
dc.contributor.author | Yoo, John | |
dc.contributor.author | MacNeil, S. D | |
dc.contributor.author | Mendez, Adrian | |
dc.contributor.author | Winquist, Eric | |
dc.contributor.author | Read, Nancy | |
dc.contributor.author | Venkatesan, Varagur | |
dc.contributor.author | Kuruvilla, Sara | |
dc.contributor.author | Warner, Andrew | |
dc.contributor.author | Mitchell, Sylvia | |
dc.contributor.author | Corsten, Martin | |
dc.contributor.author | Rajaraman, Murali | |
dc.contributor.author | Johnson-Obaseki, Stephanie | |
dc.contributor.author | Eapen, Libni | |
dc.contributor.author | Odell, Michael | |
dc.contributor.author | Chandarana, Shamir | |
dc.contributor.author | Banerjee, Robyn | |
dc.contributor.author | Dort, Joseph | |
dc.contributor.author | Matthews, T. W | |
dc.contributor.author | Hart, Robert | |
dc.contributor.author | Kerr, Paul | |
dc.contributor.author | Dowthwaite, Samuel | |
dc.contributor.author | Gupta, Michael | |
dc.contributor.author | Zhang, Han | |
dc.contributor.author | Wright, Jim | |
dc.contributor.author | Parker, Christina | |
dc.contributor.author | Wehrli, Bret | |
dc.contributor.author | Kwan, Keith | |
dc.contributor.author | Theurer, Julie | |
dc.contributor.author | Palma, David A | |
dc.date.accessioned | 2020-02-16T01:02:35Z | |
dc.date.available | 2020-02-16T01:02:35Z | |
dc.date.issued | 2020-02-14 | |
dc.date.updated | 2020-02-16T01:02:35Z | |
dc.description.abstract | Abstract Background Patients with human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPC) have substantially better treatment response and overall survival (OS) than patients with HPV-negative disease. Treatment options for HPV+ OPC can involve either a primary radiotherapy (RT) approach (± concomitant chemotherapy) or a primary surgical approach (± adjuvant radiation) with transoral surgery (TOS). These two treatment paradigms have different spectrums of toxicity. The goals of this study are to assess the OS of two de-escalation approaches (primary radiotherapy and primary TOS) compared to historical control, and to compare survival, toxicity and quality of life (QOL) profiles between the two approaches. Methods This is a multicenter phase II study randomizing one hundred and forty patients with T1–2 N0–2 HPV+ OPC in a 1:1 ratio between de-escalated primary radiotherapy (60 Gy) ± concomitant chemotherapy and TOS ± de-escalated adjuvant radiotherapy (50–60 Gy based on risk factors). Patients will be stratified based on smoking status (< 10 vs. ≥ 10 pack-years). The primary endpoint is OS of each arm compared to historical control; we hypothesize that a 2-year OS of 85% or greater will be achieved. Secondary endpoints include progression free survival, QOL and toxicity. Discussion This study will provide an assessment of two de-escalation approaches to the treatment of HPV+ OPC on oncologic outcomes, QOL and toxicity. Results will inform the design of future definitive phase III trials. Trial Registration Clinicaltrials.gov identifier: NCT03210103. Date of registration: July 6, 2017, Current version: 1.3 on March 15, 2019. | |
dc.identifier.citation | BMC Cancer. 2020 Feb 14;20(1):125 | |
dc.identifier.doi | https://doi.org/10.1186/s12885-020-6607-z | |
dc.identifier.uri | http://hdl.handle.net/1880/111650 | |
dc.identifier.uri | https://doi.org/10.11575/PRISM/45650 | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s). | |
dc.title | Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial | |
dc.type | Journal Article |